Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Foralumab is the first fully human anti-CD3 monoclonal antibody administered via the intranasal route. This novel, non-systemic approach is designed to engage regulatory T cells, promoting immune ...

with a lead focus on its fully human anti-CD3 monoclonal antibody, Foralumab, for conditions such as secondary progressive multiple sclerosis, Alzheimer’s disease, and ALS. The stock has surged ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotechnology company developing innovative immunotherapies for ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Context Therapeutics Inc.’s CNTX share price has dipped by 5.62%, which has investors questioning if this is right time to ...

Regeneron Pharmaceuticals (Nasdaq: REGN) today announced that the European Commission (EC) has granted conditional marketing ...